|Pulmatrix Inc -- USA Stock|| |
USD 1.26 0.02 1.61%
CEO and President and Director
Dr. Robert W. Clarke, Ph.D., is Chief Executive Officer and Director of the Company. Dr. Clarke has served as our chief executive officer and director since June 15, 2015, and he was the chief executive officer and director of Pulmatrix Operating since July 2012. Dr. Clarke joined Pulmatrix Operating in April 2004 as its first Ph.D. scientist and served as Chief Scientific Officer from May 2011 to September 2012, where he oversaw the research and development efforts focused on the iCALM and iSPERSE technologies. Prior to joining our Company, Mr. Clarke served as an Associate Director of Life Sciences at Alkermes, Inc. focusing on the development of inhaled therapeutic products based on the Advanced Inhalation Research technology. Dr. Clarke holds a B.Sc. in Biomedical Engineering from Boston University and received his Ph.D. in Physiology from Johns Hopkins University
Age: 46 CEO Since 2015 Ph.D
Clarke also completed postdoctoral training in Respiratory Biology at Brigham and Women?s Hospital and Harvard University. As a result of Dr. Clarke?s more than twenty years of experience in the healthcare industry and his focus on pulmonary drug delivery and the role of inhaled particles in respiratory biology and medicine, including coauthorship of over eighty chapters, papers, and abstracts, we believe that Dr. Clarke is qualified to serve as a member of the Board.
Robert Clarke Latest Insider Activity
The company has return on total asset (ROA)
of (48.95) %
which means that it has lost $48.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (154.45) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.9 M in liabilities with Debt to Equity (D/E) ratio of 30.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.14 suggesting that it may have difficulties to pay its financial obligations when they are due.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 24 people.Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 24 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.